Anetoderma
24.06.2014
Primary anetoderma of Schweninger-Buzzi type – a cutaneous sign for prothrombotic stage
INTRODUCTION Anetodermas are rare disorders of the connective tissue characterized by localized elastolysis of dermal elastin and/ or fibrillin fibres. They can be subdivided into primary or connatal anetoderma and acquired anetoderma, with the latter being more common [1, 2]. Primary anetoderma often relates to infants prematurity [3]. A great variety of trigger factors have been identified for acquired anetoderma including […]
News
21.09.2016
Cynosure Receives Approval to Market SculpSure® in South Korea
“MFDS approval of SculpSure is another major step in our international growth strategy for this breakthrough non-invasive fat-reduction treatment,” said Cynosure President and Chief Executive Officer Michael Davin. “As one of the world’s fastest-growing medical aesthetic regions, the Asia Pacific market is an important one for SculpSure and our entire product portfolio. Our Asia-Pac subsidiaries […]
18.05.2016
Almirall’s Q1 results 2016: on track to achieve yearly guidance
– Net Sales +2.7%, benefiting from contribution of new businesses – Growth driven by Dermatology +13.3%, which now accounts for 43% of sales vs. 39% in Q1 15 – Product mix drove Gross Margin improvement of +40bps – Integration of new businesses on track – R&D pipeline continues to progress: 3 Phase III programs – […]
24.05.2016
Almirall and Bicosome enter into a collaboration and sublicense agreement for the development of topical drug delivery formulations
Almirall S.A., the global pharmaceutical company based in Barcelona, and Bicosome, a start-up company that develops and commercializes high performance cosmetic and dermopharmaceutical ingredients, announced that they have entered into a research, collaboration and sublicense agreement for the development of multiple topical dermatological products, based upon Bicosome’s proprietary patented delivery technology platform, Bicosome® Technology. In […]